Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.51 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12013949 | 0.86 | P4HTM (0.50) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3405290 | 0.83 | MAPK14 (0.51) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL3408888 | 0.81 | MAPK14 (0.73) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3407562 | 0.79 | MAPK14 (0.78) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL3405640 | 0.79 | MAPK14 (0.68) | P4HTMMAPK14 | |
| SCHEMBL28478360 | 0.78 | RAB9A (1.00) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL3408404 | 0.78 | P4HTM (0.47) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3409280 | 0.77 | P4HTM (0.53) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3405644 | 0.77 | MCHR1 (0.53) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4290205 | 0.77 | RAB9A (0.70) | RAB9ANPC1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2258687-B1 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100215652-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | ASTON NICOLA MARY | 2010-08-26 | — | — | US | disclosed |
| US-7514456-B2 | Nicotinamide derivatives useful as p38 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-7125898-B2 | Nicotinamide derivatives useful as p38 inhibitors. | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
| EP-1474395-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068747-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | RAB9A 1389/4885NPC1 1358/4885ALDH1A1 723/4885 |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | RAB9A 1389/4885NPC1 1358/4885ALDH1A1 723/4885 |
| US-20100215652-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | MAPK1, MAPK7, MAPK4 | RAB9A 1582/4885NPC1 1409/4885ALDH1A1 539/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | RAB9A 1389/4885NPC1 1358/4885ALDH1A1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.